Mefenam

Mefenamic acid, the active ingredient in Mefenam, is a nonsteroidal anti-inflammatory drug presented as an oral dosage form for oral use. It treats mild to moderate pain, menstrual dysmenorrhea, and inflammatory musculoskeletal conditions.

GNH USA supplies Mefenam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mefenamic acid is used to manage pain and inflammation within musculoskeletal and gynecologic pathways.

- Mild to moderate pain: provides analgesic relief for acute or chronic pain conditions. - Menstrual dysmenorrhea: reduces uterine cramping and associated discomfort. - Inflammatory musculoskeletal conditions: alleviates inflammation and pain in joints and soft tissues.

Mefenamic acid may cause a range of adverse reactions, varying from frequent to rare.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Gastrointestinal bleeding: serious hemorrhage that may require medical intervention. - Renal impairment: acute kidney injury, especially in patients with pre‑existing renal risk. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

Before prescribing mefenamic acid, clinicians should consider several safety precautions. - Assess renal function: avoid use in patients with severe renal impairment. - Monitor gastrointestinal risk: patients with ulcer disease may need gastro‑protective therapy. - Check cardiovascular status: NSAIDs can increase blood pressure and cardiovascular events. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Concurrent anticoagulants: increased bleeding risk, monitor coagulation parameters. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Mefenamic acid can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Lithium: increased serum lithium levels, risk of toxicity. - Methotrexate: reduced clearance, potential toxicity.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: additive bleeding risk. - Diuretics: may enhance renal adverse effects.